Clinical Trial Update: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SBRT with cetuximab, with or without docetaxel, followed by adjuvant cetuximab +/- docetaxel in recurrent, previously irradiated squamo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Heath Skinner | Conditions: Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer | Phase 2 | Status: COMPLETED